Moderna signs supply deal with U.K. for COVID-19 vaccine

/ / News

Shares of Moderna Inc. were down 1.8% in premarket trading on Tuesday after it announced a new supply deal with the United Kingdom government for its experimental COVID-19 vaccine. Per the terms, Moderna will begin supplying the government with its vaccine candidate in March if it’s approved by U.K. health regulators. The company on Monday announced that its vaccine generated a 94.5% efficacy rate in a Phase 3 clinical trial, making it the second drugmaker to announce that a COVID-19 vaccine candidate was at least 90% efficacious in preventing symptomatic infections with the coronavirus. Moderna’s stock has soared 400.7% so far this year. The S&P 500 has gained 12.2% year-to-date.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.